Boston Trust Walden Corp Makes New $54.11 Million Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Boston Trust Walden Corp acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 478,073 shares of the medical equipment provider's stock, valued at approximately $54,108,000. Boston Trust Walden Corp owned 0.24% of Zimmer Biomet as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of ZBH. Dodge & Cox raised its stake in Zimmer Biomet by 12.0% during the fourth quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock worth $2,019,480,000 after purchasing an additional 2,044,645 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Zimmer Biomet by 1.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock worth $1,559,147,000 after acquiring an additional 176,337 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Zimmer Biomet by 398.7% in the fourth quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock worth $369,469,000 after acquiring an additional 2,796,372 shares in the last quarter. Northern Trust Corp increased its position in shares of Zimmer Biomet by 7.6% in the fourth quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider's stock worth $250,367,000 after acquiring an additional 167,435 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth $216,223,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the business's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the sale, the insider now directly owns 20,424 shares in the company, valued at approximately $1,940,280. The trade was a 4.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.39% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ZBH has been the subject of several recent research reports. Canaccord Genuity Group dropped their price objective on shares of Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a research report on Monday, May 12th. Robert W. Baird dropped their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Stifel Nicolaus set a $115.00 price objective on shares of Zimmer Biomet and gave the stock a "buy" rating in a research report on Tuesday, May 6th. JMP Securities lowered their price target on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. Finally, BTIG Research reaffirmed a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of "Hold" and an average target price of $111.53.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock traded up $0.67 during trading hours on Friday, reaching $91.22. The company's stock had a trading volume of 4,060,771 shares, compared to its average volume of 1,802,564. The company's 50 day simple moving average is $95.51 and its 200 day simple moving average is $102.99. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.46 and a current ratio of 2.44. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $116.71. The stock has a market cap of $18.05 billion, a P/E ratio of 20.18, a price-to-earnings-growth ratio of 2.09 and a beta of 0.72.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The firm had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. Zimmer Biomet's quarterly revenue was up 1.1% compared to the same quarter last year. During the same period last year, the firm posted $1.94 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be given a $0.24 dividend. The ex-dividend date is Thursday, June 26th. This represents a $0.96 annualized dividend and a yield of 1.05%. Zimmer Biomet's dividend payout ratio is presently 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.